全文获取类型
收费全文 | 31780篇 |
免费 | 2238篇 |
国内免费 | 463篇 |
专业分类
耳鼻咽喉 | 204篇 |
儿科学 | 329篇 |
妇产科学 | 396篇 |
基础医学 | 3416篇 |
口腔科学 | 473篇 |
临床医学 | 2064篇 |
内科学 | 2547篇 |
皮肤病学 | 2229篇 |
神经病学 | 994篇 |
特种医学 | 827篇 |
外国民族医学 | 291篇 |
外科学 | 2398篇 |
综合类 | 5353篇 |
现状与发展 | 2篇 |
一般理论 | 1篇 |
预防医学 | 2318篇 |
眼科学 | 703篇 |
药学 | 3846篇 |
1篇 | |
中国医学 | 2017篇 |
肿瘤学 | 4072篇 |
出版年
2023年 | 264篇 |
2022年 | 291篇 |
2021年 | 545篇 |
2020年 | 565篇 |
2019年 | 711篇 |
2018年 | 732篇 |
2017年 | 567篇 |
2016年 | 543篇 |
2015年 | 680篇 |
2014年 | 4632篇 |
2013年 | 3596篇 |
2012年 | 2742篇 |
2011年 | 2497篇 |
2010年 | 3859篇 |
2009年 | 3575篇 |
2008年 | 1754篇 |
2007年 | 796篇 |
2006年 | 720篇 |
2005年 | 690篇 |
2004年 | 586篇 |
2003年 | 506篇 |
2002年 | 438篇 |
2001年 | 350篇 |
2000年 | 299篇 |
1999年 | 243篇 |
1998年 | 196篇 |
1997年 | 185篇 |
1996年 | 213篇 |
1995年 | 154篇 |
1994年 | 121篇 |
1993年 | 134篇 |
1992年 | 117篇 |
1991年 | 98篇 |
1990年 | 68篇 |
1989年 | 69篇 |
1988年 | 56篇 |
1987年 | 59篇 |
1986年 | 51篇 |
1985年 | 99篇 |
1984年 | 101篇 |
1983年 | 69篇 |
1982年 | 81篇 |
1981年 | 72篇 |
1980年 | 76篇 |
1979年 | 48篇 |
1978年 | 48篇 |
1977年 | 27篇 |
1976年 | 39篇 |
1975年 | 32篇 |
1972年 | 26篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
【摘要】 目的 明确1个LEOPARD综合征家系的PTPN11基因突变。方法 对中国科学院大学宁波华美医院确诊的1例LEOPARD综合征先证者的家系进行现场调查。提取家系内4例患者、2例健康成员及与该家系无关的100例健康对照外周血标本。PCR扩增PTPN11基因所有外显子,使用Sanger测序法进行突变位点分析。结果 该家系3代14人,其中6人患病(男3例,女3例),符合常染色体显性遗传。患者皮损主要分布于面部、躯干和四肢,具有特殊面容及心血管系统异常。4例患者存在PTPN11基因的错义突变c.1632G>T(p.R558L),导致第558位由精氨酸变为亮氨酸,该突变既往未曾报道。该家系2例健康成员及100例健康对照未发现PTPN11基因突变。结论 该LEOPARD综合征家系患者PTPN11基因13号外显子发生c.1632G>T错义突变,可能是该家系患者发病的分子基础。 相似文献
3.
驱动基因的发现及针对驱动基因的靶向治疗已显著提高了肺癌患者的生存质量和时间,但目前对于BRAF、HER2、MET、RET等少见驱动基因改变肺癌患者的靶向药物的选择仍然较少。近年来免疫检查点抑制剂在肺癌治疗中取得了一定的疗效,但因为少见驱动基因突变的肺癌患者本身样本量少,开展大规模临床随机对照试验尚存在一定的困难,目前此类患者接受免疫检查点抑制剂治疗的疗效情况仍不明确。本文将对目前已掌握的免疫检查点抑制剂治疗BRAF、HER2、MET、RET等少见驱动基因改变肺癌患者的临床研究结果进行综述,以期在一定程度上为临床工作提供一些依据和参考。 相似文献
4.
目的 经口腔前庭腔镜甲状腺癌根治术的临床实践及与开放性手术进行比较。方法 回顾性收集并比较分析自2019年3月至2019年12月中国科学院大学宁波华美医院甲状腺外科行经口腔前庭腔镜甲状腺切除术和传统开放性甲状腺切除术的甲状腺肿瘤患者各45例临床资料(行经传统开放术式患者样本量较大,随机抽样选择45例),比较分析两组在性别、年龄、BMI、病理类型,清扫淋巴结数量以及手术时长,术后引流量,术后出现相关并发症,远期预后等指标。结果 两种术式患者术前术后相关临床资料无明显统计学差异,术中指标如出血量,淋巴清扫方面两组亦无统计学差异,但术中手术时间较开放组延长(P<0.05),手术费用较开放组更多,住院时长较开放组更短。结论 选择合适的患者,行经口腔前庭入路腔镜甲状腺癌根治术安全可行,在美容效果上有优势。 相似文献
5.
6.
7.
Spitz tumours comprise a spectrum of melanocytic proliferations that share a set of distinct cytological features and molecular pathways. They include benign naevi, intermediate or indeterminate tumours and rare melanomas. Spitz tumours are notorious for the difficulty of distinguishing benign neoplasms with atypical features from melanomas and the related diagnostic uncertainty. Advances in the knowledge of the molecular pathways and genomic aberrations associated with these neoplasms have permitted opportunities for a reduction in the number of uncertain diagnoses and a more objective distinction between Spitz tumours from Spitz-like neoplasms. The presence of a Spitz molecular pathway, such as Harvey rat sarcoma viral oncogene homologue (HRAS) aberrations or kinase fusions, distinguishes a bona fide Spitz neoplasm from Spitz-like naevi or melanomas with conventional driver mutations. Spitz neoplasms with benign histopathological features and, if such testing is performed, benign cytogenetic and molecular findings, are termed Spitz naevi. Spitz neoplasms with frankly malignant histopathological findings or ambiguous microscopic findings associated with genetic or genomic aberrations most in keeping with melanoma are designated as Spitz melanoma. Tumours with microscopic features and genetic/genomic aberrations in between naevi and melanomas are classified as Spitz melanocytoma. 相似文献
8.
Lorena Martin-Morales Sara Manzano Maria Rodrigo-Faus Adrian Vicente-Barrueco Victor Lorca Gonzalo Núñez-Moreno Paloma Bragado Almudena Porras Trinidad Caldes Pilar Garre Alvaro Gutierrez-Uzquiza 《International journal of cancer. Journal international du cancer》2023,152(2):283-297
Matrix metalloproteinase-11 (MMP11) is an enzyme with proteolytic activity against matrix and nonmatrix proteins. Although most MMPs are secreted as inactive proenzymes and are later activated extracellularly, MMP11 is activated intracellularly by furin within the constitutive secretory pathway. It is a key factor in physiological tissue remodeling and its alteration may play an important role in the progression of epithelial malignancies and other diseases. TCGA colon and colorectal adenocarcinoma data showed that upregulation of MMP11 expression correlates with tumorigenesis and malignancy. Here, we provide evidence that a germline variant in the MMP11 gene (NM_005940: c.232C>T; p.(Pro78Ser)), identified by whole exome sequencing, can increase the tumorigenic properties of colorectal cancer (CRC) cells. P78S is located in the prodomain region, which is responsible for blocking MMP11's protease activity. This variant was detected in the proband and all the cancer-affected family members analyzed, while it was not detected in healthy relatives. In silico analyses predict that P78S could have an impact on the activation of the enzyme. Furthermore, our in vitro analyses show that the expression of P78S in HCT116 cells increases tumor cell invasion and proliferation. In summary, our results show that this variant could modify the structure of the MMP11 prodomain, producing a premature or uncontrolled activation of the enzyme that may contribute to an early CRC onset in these patients. The study of this gene in other CRC cases will provide further information about its role in CRC development, which might improve patient treatment in the future. 相似文献
9.
10.
Aleodor A Andea 《Histopathology》2022,80(1):150-165
The work-up of melanocytic tumors has undergone significant changes in the last years following the exponential growth of molecular assays. For the practicing pathologist it is often difficult to sort through the myriad of different tests available currently for clinical use. The molecular tests used in melanocytic pathology can be broadly divided into 4 categories: (i) Tests useful in the differential diagnosis of nevus versus melanoma (primarily used as an aid in the diagnosis of histologically ambiguous melanocytic tumors), (ii) Tests that predict prognosis in melanoma, (iii) Tests useful in the classification of melanocytic tumors and (iv) Tests that predict response to systemic therapy in melanoma. This review will present an updated overview of major ancillary tests used in clinical practice. 相似文献